Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

The ASX listed whisky company actually making whisky this week

  • In News
  • February 22, 2022
  • Samantha Freidin
The ASX listed whisky company actually making whisky this week

One ASX listed whisky company is pulling a lot of attention this week thanks to a certain CEO, and not for his drinking habits. 

The Bainbridge ice saga provides a near perfect backdrop for Top Shelf International Holdings (ASX: TSI) to announce their latest deal with Coles Liquor Group. 

NED Australian Whisky and Grainshaker Hand Made Australian Vodka, two of TSI’s leading products will be made available nationwide across Coles Liquor Group’s network which includes Liquorland, First Choice Liquor and Vintage Cellars. 

The distribution agreement builds on the retail network already stocking NED Whisky which includes IGA Liquor, The Bottle-O and Cellarbrations. Grainshaker Vodka is currently available in Victoria and Queensland via IGA Liquor. 

Named after the infamous and iconic Aussie bushranger, NED Whisky aims to give “Australian dark spirits drinkers a genuine choice and something to call their own.” They’ve created a uniquely Australian whiskey, distilled and hand bottled in Melbourne. 

Seen in the hands of many at the recent Australian Open, Grainshaker Vodka is another Aussie concoction, made in Victoria. Grainshaker boasts three variations, each from a different grain: wheat, corn and rye. 

The deal aligns well with Coles Liquor Group’s latest shift, with the Group making a concerted effort to stock more high quality, locally-produced brands. 

“Securing national ranging with Coles Liquor Group is another significant milestone as we continue to build distribution of our premom Australian spirit brands to consumers around the country,” said Top Shelf CEO, Drew Fairchild.

“We are thrilled to have secured this agreement and look forward to developing a partnership with CLG that helps NED and Grainshaker further consolidate their position as leaders in their respective categories, and through this relationship, supporting the continued growth of Australia’s craft spirits industry.

“It is an example of the company’ growing momentum and continued execution of the catalysts to deliver on our strategic objectives.” 

The spirits market in Australia is on the rise. The trend of premiumisation has seen revenue in the spirits segment projected to climb to USD $411 million in 2022. The market is expected to continue its growth trajectory by 5.18% (CAGR 2022-2025).

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx tsi
  • drew fairchild
  • grainshaker
  • ned whisky
  • top shelf international holdings
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.